Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CUE Stock Forecast 2025-2026
$0.48
Current Price
$38.98M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CUE Price Targets
+1,157.1%
To High Target of $6.00
+947.6%
To Median Target of $5.00
+738.0%
To Low Target of $4.00
CUE Price Momentum
-12.7%
1 Week Change
-29.4%
1 Month Change
-56.0%
1 Year Change
-56.0%
Year-to-Date Change
-72.7%
From 52W High of $1.75
+0.5%
From 52W Low of $0.47
📊 TOP ANALYST CALLS
Did CUE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cue Biopharma is one of their latest high-conviction picks.
Latest CUE Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, CUE has a bullish consensus with a median price target of $5.00 (ranging from $4.00 to $6.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.48, the median forecast implies a 947.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Maury Raycroft at Jefferies, projecting a 1,157.1% upside. Conversely, the most conservative target is provided by Dev Prasad at LUCID CAPITAL MARKETS, suggesting a 738.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CUE Analyst Ratings
2
Buy
0
Hold
0
Sell
CUE Price Target Range
Low
$4.00
Average
$5.00
High
$6.00
Current: $0.48
Latest CUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 25, 2025 | LUCID CAPITAL MARKETS | Dev Prasad | Buy | Initiates | $4.00 |
| Apr 2, 2025 | Citizens Capital Markets | Reni Benjamin | Market Outperform | Reiterates | $2.00 |
| Aug 20, 2024 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Jul 26, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $2.00 |
| Jul 26, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $3.00 |
| Apr 9, 2024 | Stifel | Stephen Willey | Buy | Maintains | $8.00 |
| Apr 9, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $10.00 |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $8.00 |
| Mar 13, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $6.00 |
| Nov 6, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $8.00 |
| Jun 26, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Assumes | $10.00 |
| Jun 15, 2023 | Stifel | Stephen Willey | Buy | Reiterates | $8.00 |
| May 15, 2023 | JMP Securities | Reni Benjamin | Outperform | Reiterates | $15.00 |
| Mar 22, 2023 | Stifel | Stephen Willey | Buy | Maintains | $8.00 |
| Mar 22, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $10.00 |
| Nov 21, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Initiates | $7.00 |
| Aug 24, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $10.00 |
| Mar 21, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $26.00 |
| Mar 18, 2022 | Craig-Hallum | Robin Garner | Buy | Maintains | $26.00 |
| Nov 24, 2020 | Berenberg | Buy | Initiates | $N/A |
Cue Biopharma Inc. (CUE) Competitors
The following stocks are similar to Cue Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cue Biopharma Inc. (CUE) Financial Data
Cue Biopharma Inc. has a market capitalization of $38.98M with a P/E ratio of -0.7x. The company generates $7.10M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -35.6% quarter-over-quarter, while maintaining an operating margin of -351.0% and return on equity of -195.2%.
Valuation Metrics
Market Cap
$38.98M
Enterprise Value
$28.97M
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
5.3x
Growth & Margins
Revenue Growth (YoY)
-35.6%
Gross Margin
N/A
Operating Margin
-351.0%
Net Margin
0.0%
EPS Growth
-35.6%
Financial Health
Cash/Price Ratio
+54.3%
Current Ratio
1.7x
Debt/Equity
46.6x
ROE
-195.2%
ROA
-62.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cue Biopharma Inc. (CUE) Business Model
About Cue Biopharma Inc.
What They Do
Develops innovative biologic drugs for immune modulation.
Business Model
Cue Biopharma generates revenue by developing and commercializing biologic drugs that target the immune system. The company's proprietary Immuno-STAT platform allows for precise manipulation of immune responses, aiming to create therapies for diseases such as cancer and autoimmune disorders.
Additional Information
Founded in 2014 and based in Massachusetts, Cue Biopharma is positioned within the growing biotechnology sector, focusing on precision medicine and immunotherapy. The increasing demand for personalized medicine enhances the company's market potential and aligns it with current healthcare trends.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
41
CEO
Dr. Usman Azam M.D.
Country
United States
IPO Year
2018
Website
www.cuebiopharma.comCue Biopharma Inc. (CUE) Latest News & Analysis
Latest News
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
28 days ago
Quick Summary
Cue Biopharma entered a $15M licensing agreement with ImmunoScape for a cell therapy for solid tumors and announced leadership changes to advance its autoimmune therapy, CUE-401.
Why It Matters
Cue Biopharma's collaboration with ImmunoScape and leadership transition signal potential growth and innovation in cancer and autoimmune therapies, which may enhance investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cue Biopharma, Inc. reported a quarterly loss of $0.07 per share, better than the expected loss of $0.10, and an improvement from a loss of $0.17 per share a year earlier.
Why It Matters
Cue Biopharma's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and influencing stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cue Biopharma and ImmunoScape have formed a collaboration to advance a novel T cell therapy targeting solid tumors, with IND-enabling studies expected for submission in 2027.
Why It Matters
The collaboration between Cue Biopharma and ImmunoScape could lead to breakthrough cancer therapies, potentially increasing market value and investor interest in innovative biopharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Usman Azam, M.D., will become President and CEO of Cue Biopharma on September 29, 2025. The company is focusing on autoimmune diseases and advancing CUE-401 into clinical trials.
Why It Matters
The leadership change and focus on autoimmune diseases signal a strategic shift for Cue Biopharma, potentially influencing its stock performance and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
3 months ago
Quick Summary
Cue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside chat at the Cantor Global Healthcare Conference in New York from September 3-5, 2025.
Why It Matters
Cue Biopharma's participation in a major healthcare conference signals potential investor interest and insights into its pipeline, which could influence stock performance and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
3 months ago
Quick Summary
Cue Biopharma, Inc. (Nasdaq: CUE) reported its Q2 2025 business and financial update, focusing on its development of therapeutics for autoimmune diseases and cancer.
Why It Matters
Cue Biopharma's financial update may signal its progress in drug development, impacting stock performance and investor sentiment regarding its potential in autoimmune and cancer treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CUE Stock
What is Cue Biopharma Inc.'s (CUE) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Cue Biopharma Inc. (CUE) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $4.00.
Is CUE stock a good investment in 2026?
According to current analyst ratings, CUE has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CUE stock?
Wall Street analysts predict CUE stock could reach $5.00 in the next 12 months. This represents a 947.6% increase from the current price of $0.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cue Biopharma Inc.'s business model?
Cue Biopharma generates revenue by developing and commercializing biologic drugs that target the immune system. The company's proprietary Immuno-STAT platform allows for precise manipulation of immune responses, aiming to create therapies for diseases such as cancer and autoimmune disorders.
What is the highest forecasted price for CUE Cue Biopharma Inc.?
The highest price target for CUE is $6.00 from Maury Raycroft at Jefferies, which represents a 1,157.1% increase from the current price of $0.48.
What is the lowest forecasted price for CUE Cue Biopharma Inc.?
The lowest price target for CUE is $4.00 from Dev Prasad at LUCID CAPITAL MARKETS, which represents a 738.0% increase from the current price of $0.48.
What is the overall CUE consensus from analysts for Cue Biopharma Inc.?
The overall analyst consensus for CUE is bullish. Out of 9 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are CUE stock price projections?
Stock price projections, including those for Cue Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 2:33 AM UTC